Erythropoietin in stroke: quo vadis

Bibliography

• Lloyd-Jones D, Adams R, Carnethon M, Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):480-6
   PubMed Web of Science ®Google Scholar
• California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64(4):654-9
   PubMed Web of Science ®Google Scholar
• Kleindorfer D, Lindsell CJ, Brass LV. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008;39(3):924-8
   PubMed Web of Science ®Google Scholar
• Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141(1):14-31
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Wang L, Rogers HM, Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008;10:e36. Published online 01 December 2008, doi:10.1017/S1462399408000860
   PubMedGoogle Scholar
• Elliott S, Busse L, Bass MB, Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107(5):1892-5
   PubMed Web of Science ®Google Scholar
• Kirkeby A, van Beek J, Nielsen J, Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor. J Neurosci Methods 2007;164(1):50-8
   PubMed Web of Science ®Google Scholar
• Sinclair AM, Coxon A, McCaffery I, Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Chen ZY, Warin R, Noguchi CT. Erythropoietin and normal brain development: receptor expression determines multi-tissue response. Neurodegener Dis 2006;3(1-2):68-75
   PubMed Web of Science ®Google Scholar
• Kilic E, Kilic U, Soliz J, Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. FASEB 2005;19(14):2026-8
   PubMedGoogle Scholar
• Tsai PS, Ohab JJ, Kertesz N, A critical role or erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006;26(4):1269-74
   PubMed Web of Science ®Google Scholar
• Yu X, Shacka JJ, Eells JB, Erythropoietin receptor signalling is required for normal brain development. Development 2002;129(2):505-16
   PubMed Web of Science ®Google Scholar
• Chen ZY, Asavaritikrai P, Prchal JT, Noguchi CT. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007;282(35):25875-83
   PubMed Web of Science ®Google Scholar
• Kadota T, Shingo T, Yasuhara T, Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. Brain Res 2009;1254:120-7
   PubMed Web of Science ®Google Scholar
• Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol 2006;59(5):735-42
   PubMed Web of Science ®Google Scholar
• Ohab JJ, Carmichael ST. Poststroke neurogenesis: emerging principles of migration and localization of immature neurons. Neuroscientist 2008;14(4):369-80
   PubMed Web of Science ®Google Scholar
• Morishita E, Masuda S, Nagao M, Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76(1):105-16
   PubMed Web of Science ®Google Scholar
• Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature 2001;412(6847):641-7
   PubMed Web of Science ®Google Scholar
• Sakanaka M, Wen TC, Matsuda S, In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998;95(8):4635-40
   PubMed Web of Science ®Google Scholar
• Konishi Y, Chui DH, Hirose H, Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 1993;609(1-2):29-35
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106(23):2973-9
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002;11(6):863-71
   PubMedGoogle Scholar
• Diaz Z, Assaraf MI, Miller WH Jr, Schipper HM. Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. J Neurochem 2005;93(2):392-402
   PubMed Web of Science ®Google Scholar
• Grasso G, Sfacteria A, Meli F, Neuroprotection by erythropoietin administration after experimental traumatic brain injury. Brain Res 2007;1182:99-105
   PubMed Web of Science ®Google Scholar
• Gorio A, Gokmen N, Erbayraktar S, Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci USA 2002;99(14):9450-5
   PubMed Web of Science ®Google Scholar
• Grasso G, Sfacteria A, Erbayraktar S, Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. J Neurosurg Spine 2006;4(4):310-18
   PubMed Web of Science ®Google Scholar
• Mann C, Lee JH, Liu J, Delayed treatment of spinal cord injury with erythropoietin or darbepoetin–a lack of neuroprotective efficacy in a contusion model of cord injury. Exp Neurol 2008;211(1):34-40
   PubMed Web of Science ®Google Scholar
• Li Y, Lu ZY, Ogle M, Wei L. Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice. Neurochem Res 2007;32(12):2132-41
   PubMed Web of Science ®Google Scholar
• Chi OZ, Hunter C, Liu X, Weiss HR. Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia. Pharmacology 2008;82(1):38-42
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Hasselblatt M, Dembowski C, Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):495-505
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Weissenborn K, Prange H, Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 2009;40(12):e647-56
   PubMed Web of Science ®Google Scholar
• Unger EF, Thompson AM, Blank MJ, Temple R. Erythropoiesis-stimulating agents–time for a reevaluation. N Eng J Med 2010;362(3):189-92
   PubMed Web of Science ®Google Scholar
• Kaur J, Zhao Z, Klein GM, The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab 2004;24(9):945-63
   PubMed Web of Science ®Google Scholar
• Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 2009;40(Suppl 3):S111-14
   PubMed Web of Science ®Google Scholar
• Fisher M, Bastan B. Treating acute ischemic stroke. Curr Opin Drug Discov Devel 2008;11(5):626-32
   PubMed Web of Science ®Google Scholar
• Fisher M. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke 2003;34(6):1539-46
   PubMed Web of Science ®Google Scholar
• O'Collins VE, Macleod MR, Donnan GA, 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59(3):467-77
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30(12):2752-8
   PubMed Web of Science ®Google Scholar
• Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001;32(7):1598-606
   PubMed Web of Science ®Google Scholar
• Fisher M, Albers GW, Donnan GA, Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke 2005;36(8):1808-13
   PubMed Web of Science ®Google Scholar
• Fisher M, Hanley DF, Howard G, Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke 2007;38(2):245-8
   PubMed Web of Science ®Google Scholar
• Fisher M, Feuerstein G, Howells DW, Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40(6):2244-50
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57(2):178-201
   PubMed Web of Science ®Google Scholar
• Butt AM, Jones HC, Abbott NJ. Electrical resistance across the blood–brain barrier in anaesthetized rats: a developmental study. J Physiol 1990;429:47-62
   PubMed Web of Science ®Google Scholar
• Brines ML, Ghezzi P, Keenan S, Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97(19):10526-31
   PubMed Web of Science ®Google Scholar
• Minnerup J, Heidrich J, Rogalewski A, The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis. Stroke 2009;40(9):3113-20
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Drug targeting to the brain. Pharm Res 2007;24(9):1733-44
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier delivery. Drug Discov Today 2007;12(1-2):54-61
   PubMed Web of Science ®Google Scholar
• Habgood MD, Bye N, Dziegielewska KM, Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci 2007;25(1):231-8
   PubMed Web of Science ®Google Scholar
• Banks WA, Jumbe NL, Farrell CL, Passage of erythropoietic agents across the blood–brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505(1-3):93-101
   PubMed Web of Science ®Google Scholar
• Bernaudin M, Marti HH, Roussel S, A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 1999;19(6):643-51
   PubMed Web of Science ®Google Scholar
• Wakida K, Shimazawa M, Hozumi I, Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia. Neuroscience 2007;148(1):105-14
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang ZG, Rhodes K, Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007;151(8):1377-84
   PubMed Web of Science ®Google Scholar
• Jeong Lee H, Pardridge WM. Drug targeting to the brain using avidin-biotin technology in the mouse; (blood–brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J Drug Target 2000;8(6):413-24
   PubMed Web of Science ®Google Scholar
• Spector R, Mock D. Biotin transport through the blood-brain barrier. J Neurochem 1987;48(2):400-4
   PubMed Web of Science ®Google Scholar
• Shi F, Bailey C, Malick AW, Audus KL. Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers. Pharm Res 1993;10(2):282-8
   PubMed Web of Science ®Google Scholar
• Pillai DR, Dittmar MS, Baldaranov D, Cerebral ischemia-reperfusion injury in rats-a 3 T MRI study on biphasic blood–brain barrier opening and the dynamics of edema formation. J Cereb Blood Flow Metab 2009;29(11):1846-55
   PubMed Web of Science ®Google Scholar
• Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev 2001;38(1-2):140-8
   PubMed Web of Science ®Google Scholar
• Belayev L, Busto R, Zhao W, Ginsberg MD. Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 1996;739(1-2):88-96
   PubMed Web of Science ®Google Scholar
• Martinez-Estrada OM, Rodriguez-Millan E, Gonzalez-De Vicente E, Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur J Neurosci 2003;18(9):2538-44
   PubMed Web of Science ®Google Scholar
• Barchet TM, Amiji MM. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv 2009;6(3):211-25
   PubMed Web of Science ®Google Scholar
• Wen TC, Sadamoto Y, Tanaka J, Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression. J Neurosci Res 2002;67(6):795-803
   PubMed Web of Science ®Google Scholar
• Zhang F, Signore AP, Zhou Z, Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms. J Neurosci Res 2006;83(7):1241-51
   PubMed Web of Science ®Google Scholar
• Wu H, Hu K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv 2008;5(10):1159-68
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5. Published online 10 December 2008, doi:10.1186/1471-2202-9-S3-S5
   PubMed Web of Science ®Google Scholar
• Freychet L, Rizkalla SW, Desplanque N, Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet 1988;1(8599):1364-6
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Thorne RG, Intranasal administration of insulin-like growth factor-I bypasses the blood–brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 2001;187(1-2):91-7
   PubMed Web of Science ®Google Scholar
• Liu XF, Fawcett JR, Thorne RG, Frey WH 2nd. Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neurosci Lett 2001;308(2):91-4
   PubMed Web of Science ®Google Scholar
• Ross TM, Martinez PM, Renner JC, Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 2004;151(1-2):66-77
   PubMed Web of Science ®Google Scholar
• Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004;127(2):481-96
   PubMed Web of Science ®Google Scholar
• Yu YP, Xu QQ, Zhang Q, Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 2005;387(1):5-10
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH 2nd, Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006;27(3):451-8
   PubMed Web of Science ®Google Scholar
• Thorne RG, Hanson LR, Ross TM, Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 2008;152(3):785-97
   PubMed Web of Science ®Google Scholar
• Francis GJ, Martinez JA, Liu WQ, Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 2008;131(Pt 12):3311-34
   PubMedGoogle Scholar
• Ma M, Ma Y, Yi X, Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci 2008;9:117. Published online 10 December 2008, doi:10.1186/ 1471-2202-9-117
   PubMedGoogle Scholar
• Martinez JA, Francis GJ, Liu WQ, Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis. Neuroscience 2008;157(4):908-25
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Green PS, Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 2008;13(3):323-31
   PubMed Web of Science ®Google Scholar
• Ross TM, Zuckermann RN, Reinhard C, Frey WH 2nd. Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett 2008;439(1):30-3
   PubMed Web of Science ®Google Scholar
• Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept 2009;154(1-3):107-11
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez JC, Sosa-Teste I. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans. ScientificWorld Journal 2009;9:970-81
   PubMed Web of Science ®Google Scholar
• Hanson L, Roeytenberg A, Martinez PM, Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 2009;330(3):679-86
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 2009;98(7):2501-15
   PubMed Web of Science ®Google Scholar
• Fletcher L, Kohli S, Sprague SM, Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. J Neurosurg 2009;111(1):164-70
   PubMed Web of Science ®Google Scholar
• Alcala-Barraza SR, Lee MS, Hanson LR, Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18(3):179-90
   PubMed Web of Science ®Google Scholar
• Yu H, Kim K. Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits. Int J Pharm 2009;378(1-2):73-9
   PubMedGoogle Scholar
• Hanson LR, Frey WH 2nd. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007;2(1):81-6
   PubMed Web of Science ®Google Scholar
• Pietrowsky R, Struben C, Molle M, Brain potential changes after intranasal vs intravenous administration of vasopressin: evidence for a direct nose–brain pathway for peptide effects in humans. Biol Psychiatry 1996;39(5):332-40
   PubMed Web of Science ®Google Scholar
• Pietrowsky R, Thiemann A, Kern W, A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996;21(6):559-72
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010;99(4):1654-73
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Roccaro AM, Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33(10):891-6
   PubMed Web of Science ®Google Scholar
• Muller-Ehmsen J, Schmidt A, Krausgrill B, Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 2006;290(1):H331-40
   PubMed Web of Science ®Google Scholar
• Juul SE, Beyer RP, Bammler TK, Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009;65(5):485-92
   PubMed Web of Science ®Google Scholar
• Mahmood A, Lu D, Qu C, Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J Neurosurg 2007;107(2):392-7
   PubMed Web of Science ®Google Scholar
• Danielyan L, Schafer R, von Ameln-Mayerhofer A, Intranasal delivery of cells to the brain. Eur J Cell Biol 2009;88(6):315-24
   PubMed Web of Science ®Google Scholar
• Balin BJ, Broadwell RD, Salcman M, el-Kalliny M. Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 1986;251(2):260-80
   PubMed Web of Science ®Google Scholar
• Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56(1):3-17
   PubMed Web of Science ®Google Scholar
• Merkus FW, van den Berg MP. Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory. Drugs R D 2007;8(3):133-44
   PubMedGoogle Scholar
• Digicaylioglu M, Garden G, Timberlake S, Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci USA 2004;101(26):9855-60
   PubMed Web of Science ®Google Scholar
• Diem R, Sattler MB, Merkler D, Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 2005;128(Pt 2):375-85
   PubMedGoogle Scholar
• Faure S, Oudart N, Javellaud J, Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. J Hypertens 2006;24(11):2255-61
   PubMed Web of Science ®Google Scholar
• van der Kooij MA, Groenendaal F, Kavelaars A, Combination of deferoxamine and erythropoietin: therapy for hypoxia–ischemia-induced brain injury in the neonatal rat? Neurosci Lett 2009;451(2):109-13
   PubMed Web of Science ®Google Scholar
• Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010;141(3):265-76
   PubMed Web of Science ®Google Scholar
• Jerndal M, Forsberg K, Sena ES, A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Li Y, Lu Z, Keogh CL, Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 2007;27(5):1043-54
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Z, Wang Y, Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35(7):1732-7
   PubMed Web of Science ®Google Scholar
• Villa P, Bigini P, Mennini T, Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Exp Med 2003;198(6):971-5
   PubMed Web of Science ®Google Scholar
• Sadamoto Y, Igase K, Sakanaka M, Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 1998;253(1):26-32
   PubMed Web of Science ®Google Scholar